Testing Urine and Blood Cells to Study Urinary Tract Cancers
Studies cells from urine and blood to help predict outcomes in bladder cancer patients.
Key facts
- Who runs it
- IRCCS San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Liquid Biospy for Urinary Cancers
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 29 Sept 2020
- Expected to end
- 29 Sept 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Genetic analysis on isolated cells
- Record updated
- 7 November 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with a newly diagnosed urothelial tumor (bladder or upper urinary tract) who have not had treatment yet.
- Age
- 40 Years or older
- Sex
- Men and women can join.
- Disease stage
- Urothelial neoplasia (cancer of the urinary tract lining).
- Earlier treatment
- People must not have had therapy for it before (treatment-naive).
Main reasons for not taking part
- The record lists the absence of previous neoplastic disease or genetic diseases as an exclusion, as written.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosis of urothelial neoplasia, naive for therapy
Who cannot take part
- Absence of previous neolpastic disease or genetic diseases
Where in Italy
- Urology DepartmentMilan, ItalyContact: Andrea Salonia, MD, PhDTaking people
About the trial
What the trial wants to find out
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by CTCs.
The 2 groups in the trial
- 1
Urothelial neoplasia
Treatment: Genetic analysis on isolated cells
- 2
Age-matched individuals free of neoplasia
Treatment: Genetic analysis on isolated cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer"
- Plain-language title
- Testing Urine and Blood Cells to Study Urinary Tract CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 November 2023